Health care payments giant Zelis is weighing strategic options — including a potential sale or IPO — that could value it at $15 billion-plus, Axios has confirmed.
Why it matters: Zelis is considered a blue-chip asset by most funds — the outcome of its process will be a helpful tell of where market appetite sits.
